-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
![Volition scientist packing Nu.Q test](https://volition.com/wp-content/uploads/2023/05/Volition_231019_0460.jpg)
Nu.Q® Discover – Markets & Markets Next-Gen Immuno-Oncology Conference
- Share
- Tweet
- Share on Facebook
- Share
![Screenshot 2024-03-08 132535](https://volition.com/wp-content/uploads/2024/03/Screenshot-2024-03-08-132535.png)
Volition attended the Markets and Markets Next-Gen Immuno-Oncology Conference in London, March 2024. Hear from Dharmik Rawal, Volition Director Strategy & Product Launches, about how the conference went and the scope of our Nu.Q® Discover programme.
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields